Neoadjuvant T-DM1/pertuzumab and paclitaxel/trastuzumab/pertuzumab for HER2+ breast cancer in the adaptively randomized I-SPY2 trialAmy S. Clark, Laura J. Esserman, Erin D. Ellis et al.|Nature Communications|2021Cited by 73
Mammary-specific expression of Trim24 establishes a mouse model of human metaplastic breast cancerVrutant Shah, Michelle Barton, Aundrietta D. Duncan et al.|Nature Communications|2021Cited by 43
Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancerDouglas Yee, Jane Perlmutter, Claudine Isaacs et al.|npj Breast Cancer|2021Cited by 29
An Annotated Biobank of Triple-Negative Breast Cancer Patient-Derived Xenografts Features Treatment-Naïve and Longitudinal Samples during Neoadjuvant ChemotherapyAmanda L. Rinkenbaugh, Helen Piwnica‐Worms, Yuan Qi et al.|Cancer Research|2025Cited by 2
Abstract 1513: Analysis of spatiotemporal phenotypic heterogeneity in chemoresistant triple negative breast cancer using imaging mass cytometryAmanda L. Rinkenbaugh, Helen Piwnica‐Worms, Vidya C. Sinha et al.|Cancer Research|2020Cited by 1